Source: NewsMaker

Press Release: IBI : Proliferative Diabetic Retinopathy (PDR) Therapeutic Pipeline Market Review, H1 2016

Summary...

Read full article »
IBI's Competitors | IBI's News | IBI's Financials
Stay up-to-date with the latest news on Icon Bioscience, Inc.
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
David S Tierney's photo - President & CEO of Icon Bioscience, Inc.

President & CEO

David S Tierney

CEO Approval Rating

77/100

Read more
Stay up-to-date with the latest news on Icon Bioscience, Inc.